GO:1901874 negative regulation of post-translational protein modification: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901874 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of post-translational protein modification (PTM).
• PTMs such as phosphorylation, ubiquitination, SUMOylation, and serotonylation are reversible and their negative regulation is essential for immune signaling, cell death, and metabolism.
• Negative regulation of PTM is achieved by deconjugating enzymes, inhibitor proteins, and competitive substrates that remove or block modifying groups.
• Dysregulation of PTM removal contributes to cancer, inflammatory diseases, and viral pathogenesis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of negative regulators of PTM in disease contexts.
• Understanding GO:1901874 provides a framework for therapeutic targeting of enzymes that reverse PTMs, such as deubiquitinases and desumoylases.
Description
Post-translational protein modification (PTM) is a fundamental mechanism that expands the functional diversity of the proteome, controlling nearly every aspect of cell biology including signal transduction, gene expression, and immune responses. The Gene Ontology term GO:1901874, negative regulation of post-translational protein modification, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of these modifications. This term is critical for researchers because the reversible nature of PTMs means that their removal or inhibition is as important as their addition for maintaining cellular homeostasis. For example, the reversal of ubiquitination by deubiquitinases regulates NF-kB signaling and cell survival, while desumoylation controls cell death pathways. The importance of GO:1901874 extends to host-pathogen interactions, where viruses and bacteria manipulate host PTM machinery to evade immunity. Negative regulation of PTMs also plays a role in metabolic control, as seen in the serotonylation of GAPDH which is dynamically regulated to couple glycolytic metabolism with antitumor immunity. In the context of nuclear receptor signaling, the glucocorticoid receptor undergoes PTMs that are negatively regulated to fine-tune transcriptional responses. Given the broad impact of PTM reversal on disease, there is growing interest in identifying and characterizing the enzymes and regulatory proteins that execute negative regulation of PTMs. This article provides a comprehensive overview of GO:1901874, covering its definition, mechanisms, key genes, disease associations, and state-of-the-art research methods including CRISPR-based models.
negative regulation of post-translational protein modification At A Glance
| GO ID | GO:1901874 |
|---|---|
| GO term | negative regulation of post-translational protein modification |
| Ontology | biological_process |
| Synonym | negative regulation of PTM; inhibition of post-translational modification; downregulation of post-translational protein modification |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of post-translational protein modification |
| Related processes | Deubiquitination, desumoylation, dephosphorylation, inhibition of modifying enzymes |
| Key enzymes | Deubiquitinases (DUBs), desumoylases (SENPs), phosphatases, inhibitor proteins |
| Disease relevance | Cancer, inflammatory diseases, viral infections, metabolic disorders |
What Is GO:1901874?
GO:1901874, negative regulation of post-translational protein modification, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of post-translational protein modification. In other words, it encompasses biological activities that counteract the addition or removal of chemical groups to proteins after translation, such as dephosphorylation, deubiquitination, desumoylation, or inhibition of modifying enzymes. This term is a child of negative regulation of protein modification process and is distinct from positive regulation or regulation of PTM.
Why Is negative regulation of post-translational protein modification Important in Cell Biology?
Negative regulation of post-translational protein modification is essential for maintaining cellular homeostasis and preventing aberrant signaling that can lead to disease. Because PTMs are reversible, the enzymes and processes that remove or block these modifications serve as critical checkpoints in pathways such as immune response, cell death, and metabolism. For instance, the removal of ubiquitin chains by deubiquitinases can rescue proteins from degradation, thereby influencing cell survival and proliferation. Similarly, desumoylation can reverse SUMO-mediated cell death, highlighting the importance of negative regulation in cell fate decisions. In the context of viral infection, negative regulation of PTMs can either restrict viral replication or be exploited by viruses to evade host defenses. Thus, understanding GO:1901874 is fundamental for developing therapeutic strategies that target PTM reversal enzymes.
• Controls immune signaling by reversing ubiquitination and phosphorylation of key adaptors.
• Regulates cell death pathways through desumoylation of apoptotic regulators.
• Modulates metabolic reprogramming via removal of serotonylation on glycolytic enzymes.
• Influences viral restriction by altering PTM status of host restriction factors.
• Affects nuclear receptor signaling, including glucocorticoid receptor activity.
• Plays a role in cancer by regulating the stability of oncoproteins and tumor suppressors.
• Provides targets for therapeutic intervention, such as DUB inhibitors.
• Is essential for developmental processes and tissue homeostasis.
• Contributes to neurodegeneration when dysregulated.
• Offers biomarkers for disease prognosis and treatment response.
What Happens During negative regulation of post-translational protein modification?
Removal of modifying groups by deconjugating enzymes
In simple terms: Enzymes act like erasers that remove chemical tags from proteins.
The most direct mechanism of negative regulation of PTM is the enzymatic removal of modifying groups. Deubiquitinases (DUBs) cleave ubiquitin chains from target proteins, reversing ubiquitination and altering protein stability or localization. Similarly, sentrin-specific proteases (SENPs) remove SUMO moieties, thereby reversing SUMOylation and modulating processes such as cell death. Phosphatases remove phosphate groups added by kinases, counteracting phosphorylation-dependent signaling. These enzymes are highly specific and are regulated in response to cellular cues.
Inhibition of modifying enzymes
In simple terms: Proteins can block the enzymes that add chemical tags.
Negative regulation can also occur by inhibiting the enzymes that catalyze PTM addition. For example, inhibitor proteins can bind to and sequester E3 ubiquitin ligases, preventing substrate ubiquitination. In innate immunity, negative regulators such as A20 and CYLD inhibit ubiquitin ligases, thereby dampening NF-kB signaling. This mode of regulation often involves protein-protein interactions that mask the active site or promote conformational changes.
Competitive substrates and decoy molecules
In simple terms: Decoy molecules soak up the modifying enzymes so they cannot act on real targets.
Some negative regulators act as competitive substrates that titrate modifying enzymes away from their physiological targets. For instance, certain proteins contain ubiquitin-like domains that are recognized by DUBs but are not cleaved, effectively sequestering the enzyme. Similarly, decoy SUMO substrates can limit desumoylation of key regulators. This mechanism provides a buffer against excessive PTM removal and fine-tunes signaling dynamics.
Regulation of PTM reversal by post-translational modifications themselves
In simple terms: The eraser enzymes can themselves be tagged, which changes their activity.
The activity of deconjugating enzymes is often controlled by PTMs. For example, phosphorylation of DUBs can enhance or inhibit their catalytic activity, creating feedback loops. SUMOylation of SENPs can alter their subcellular localization and substrate specificity. This layered regulation ensures that negative regulation of PTM is responsive to cellular signals and integrated with other pathways.
Spatiotemporal control of negative regulation
In simple terms: Where and when the eraser acts is tightly controlled.
Negative regulation of PTM is spatially and temporally organized. Scaffold proteins can recruit deconjugating enzymes to specific subcellular compartments, such as the nucleus or mitochondria, to reverse PTMs locally. For example, the glucocorticoid receptor undergoes dynamic PTM changes that are negatively regulated in a ligand-dependent manner. This spatial control prevents inappropriate removal of PTMs and ensures signaling fidelity.
Key Genes Involved in GO:1901874 negative regulation of post-translational protein modification
The following genes encode proteins that directly or indirectly mediate negative regulation of post-translational protein modification, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYLD | Deubiquitinase that removes K63-linked ubiquitin chains | Negative regulator of NF-kB signaling; tumor suppressor |
| A20 (TNFAIP3) | Deubiquitinase and ubiquitin ligase | Inhibits NF-kB by removing ubiquitin from RIP1 |
| SENP1 | Desumoylase that removes SUMO from target proteins | Regulates cell death and survival; implicated in cancer |
| SENP2 | Desumoylase | Modulates Wnt signaling and development |
| USP7 | Deubiquitinase | Stabilizes MDM2 and MDM4; regulates p53 pathway |
| USP9X | Deubiquitinase | Regulates TGF-beta signaling and cell polarity |
| OTUB1 | Deubiquitinase | Inhibits ubiquitination of chromatin and immune regulators |
| DUB3 (USP17) | Deubiquitinase | Regulates cell cycle and DNA damage response |
| PPM1A | Protein phosphatase | Dephosphorylates SMAD proteins to inhibit TGF-beta signaling |
| PTPN11 (SHP2) | Protein tyrosine phosphatase | Negatively regulates cytokine signaling |
| GAPDH | Glycolytic enzyme with serotonylation site | Serotonylation is dynamically regulated; negative regulation impacts antitumor immunity |
| NR3C1 (GR) | Glucocorticoid receptor | PTMs including phosphorylation and ubiquitination are negatively regulated |
| MDM4 | p53 regulator | Ubiquitination and phosphorylation are negatively regulated to control p53 |
| MYOSTATIN | TGF-beta family ligand | PTM regulation affects its activity in muscle wasting |
| IKBKG (NEMO) | NF-kB essential modulator | Ubiquitination is negatively regulated to control immune signaling |
| RIPK1 | Receptor-interacting protein kinase | Ubiquitination status is negatively regulated to switch between survival and death |
| TRAF6 | E3 ubiquitin ligase | Its activity is negatively regulated by DUBs |
How Is negative regulation of post-translational protein modification Regulated?
The process of negative regulation of post-translational protein modification is itself tightly regulated at multiple levels. Transcriptionally, the expression of deubiquitinases and desumoylases can be induced by stress or immune stimuli. Post-translationally, these enzymes are modified by phosphorylation, ubiquitination, and SUMOylation, which alter their activity, stability, or localization. For example, the glucocorticoid receptor signaling pathway involves negative regulation of its own PTMs as part of feedback control. Additionally, viral proteins can hijack host negative regulators to promote immune evasion. Metabolic cues, such as serotonin levels, can influence the negative regulation of GAPDH serotonylation. Thus, the negative regulation of PTM is embedded in complex regulatory networks that ensure appropriate cellular responses.
negative regulation of post-translational protein modification and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYLD | Cancer, inflammation | Knockout cell lines, mouse models |
| USP7 | Cancer (p53 pathway) | Point mutation (catalytic dead), overexpression |
| SENP1 | Cancer, cell death | Knockout, knock-in of SUMO sites |
| TNFAIP3 (A20) | Autoimmune diseases | Knockout, point mutation (DUB-dead) |
| GAPDH | Metabolic disorders, cancer immunity | Knock-in of serotonylation site mutants |
Cancer
Dysregulation of negative regulation of PTM is a hallmark of cancer. Overexpression of deubiquitinases such as USP7 can lead to stabilization of oncoproteins like MDM4, promoting tumorigenesis. Conversely, loss of CYLD, a negative regulator of NF-kB, is associated with multiple cancers. Targeting these enzymes with small molecule inhibitors is a promising therapeutic strategy.
Inflammatory and autoimmune diseases
Negative regulators of ubiquitination, such as A20 and CYLD, are critical for preventing excessive inflammation. Mutations in TNFAIP3 (encoding A20) are linked to autoimmune disorders. The balance between ubiquitination and deubiquitination controls the duration and intensity of NF-kB signaling, and its disruption contributes to chronic inflammation.
Viral infections
Viruses encode proteins that manipulate host PTM machinery to evade immune detection. For example, some viral proteins mimic host DUBs to remove ubiquitin from immune signaling molecules, effectively negatively regulating PTM to promote viral replication. Understanding these mechanisms can inform antiviral drug development.
Neurodegenerative disorders
Impaired negative regulation of PTM can lead to accumulation of modified proteins, contributing to neurodegeneration. SUMOylation and its reversal are implicated in protein aggregation diseases. Modulating desumoylase activity may offer therapeutic benefits.
From negative regulation of post-translational protein modification-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a DUB affect substrate stability? | CRISPR knockout cell line |
| Is catalytic activity required for function? | Point mutation (catalytic dead) knock-in |
| Does a specific PTM site regulate interaction? | Point mutation (acceptor site) knock-in |
| Where does the protein localize? | Tagged knock-in (e.g., GFP) |
| Does overexpression mimic disease? | Overexpression cell line |
| Can a drug inhibit the negative regulator? | Knockout + drug treatment |
How to Study the negative regulation of post-translational protein modification Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ubiquitin remnant profiling | Global ubiquitination sites | Identify changes upon DUB knockout |
| SUMO proteomics | SUMOylated proteins | Assess desumoylase function |
| CRISPR knockout screen | Gene essentiality for PTM regulation | Discover novel negative regulators |
| In vitro DUB assay | Enzymatic activity | Validate catalytic mutants |
| Phospho-specific antibodies | Phosphorylation status | Monitor phosphatase activity |
| Proximity ligation assay | Protein-protein interactions | Detect enzyme-substrate proximity |
| Live-cell imaging | Subcellular localization | Track dynamic PTM reversal |
Proteomics and PTM-specific enrichment
Mass spectrometry-based proteomics coupled with enrichment of modified peptides (e.g., ubiquitin remnant profiling) allows global identification of PTM sites and their regulation. This method can quantify changes in ubiquitination or SUMOylation upon knockout of a negative regulator.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain alters PTM levels. For example, a screen for regulators of NF-kB ubiquitination may uncover novel DUBs.
Biochemical assays for enzyme activity
In vitro deubiquitination or desumoylation assays using recombinant enzymes and fluorogenic substrates measure catalytic activity directly. These assays are essential for validating hits from screens.
Imaging and proximity labeling
Fluorescence microscopy with tagged proteins and proximity labeling (e.g., BioID) can reveal spatiotemporal dynamics of negative regulation. For instance, tracking GFP-tagged SENP1 localization upon stress.
How CRISPR Can Be Used to Study GO:1901874 negative regulation of post-translational protein modification
Knockout
CRISPR knockout of genes encoding negative regulators of PTM (e.g., CYLD, SENP1) results in hyper-modification of substrates, leading to pathway activation or cell death. These models are invaluable for establishing causality and identifying downstream effects.
Point Mutation
Introducing catalytic-dead point mutations (e.g., C91S in CYLD) via CRISPR knock-in allows separation of enzymatic activity from scaffolding functions. Such models reveal whether negative regulation depends on catalysis.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) or of specific PTM acceptor site mutants (e.g., K-to-R ubiquitination sites) enables tracking and functional analysis of negative regulation in endogenous contexts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of negative regulators can suppress PTM levels and phenocopy loss-of-function of modifying enzymes. This approach is useful for testing therapeutic potential.
How EDITGENE Supports negative regulation of post-translational protein modification Research
Researchers studying negative regulation of post-translational protein modification-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of post-translational protein modification research.
Frequently Asked Questions About negative regulation of post-translational protein modification
What is GO:1901874?
GO:1901874 is a Gene Ontology term for negative regulation of post-translational protein modification, describing any process that stops, prevents, or reduces the frequency, rate, or extent of PTM.
What genes are involved in negative regulation of post-translational protein modification?
Key genes include CYLD, A20, SENP1, USP7, and PPM1A, which encode deubiquitinases, desumoylases, and phosphatases.
How does negative regulation of PTM affect cancer?
It controls the stability of oncoproteins and tumor suppressors; dysregulation can lead to cancer.
What are examples of negative regulation of PTM?
Deubiquitination by CYLD, desumoylation by SENP1, and dephosphorylation by PPM1A are examples.
Why is negative regulation of PTM important for immunity?
It prevents excessive immune signaling by reversing ubiquitination of NF-kB pathway components.
Can viruses manipulate negative regulation of PTM?
Yes, viruses encode proteins that mimic or hijack host negative regulators to evade immune responses.
What methods study negative regulation of PTM?
Proteomics, CRISPR screens, in vitro enzyme assays, and imaging are commonly used.
How do CRISPR knockouts help study GO:1901874?
Knockouts of negative regulators cause hyper-modification, revealing their role in pathways.
What diseases are linked to defective negative regulation of PTM?
Cancer, autoimmune diseases, viral infections, and neurodegeneration.
What is the difference between positive and negative regulation of PTM?
Positive regulation promotes modification, while negative regulation inhibits or reverses it.
Conclusion
GO:1901874, negative regulation of post-translational protein modification, is a fundamental biological process that counterbalances PTM addition to maintain cellular homeostasis. Its dysregulation is implicated in cancer, immune disorders, and viral pathogenesis. By leveraging CRISPR-based models and advanced proteomics, researchers can dissect the mechanisms and identify therapeutic targets. EDITGENE offers comprehensive services to support these investigations, from knockout to library screening.
References
- 1. Wang X et al.. 2024. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity.. Mol Cell 84(4):760-775.e7 PMID: 38215751
- 2. Oakley RH et al.. 2013. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease.. J Allergy Clin Immunol 132(5):1033-44 PMID: 24084075
- 3. Liu J et al.. 2016. Post-Translational Modification Control of Innate Immunity.. Immunity 45(1):15-30 PMID: 27438764
- 4. Chamontin C et al.. 2021. Regulation of Viral Restriction by Post-Translational Modifications.. Viruses 13(11) PMID: 34835003
- 5. Markey MP. 2011. Regulation of MDM4.. Front Biosci (Landmark Ed) 16(3):1144-56 PMID: 21196223
- 6. Sheng Z et al.. 2021. SUMOylation modification-mediated cell death.. Open Biol 11(7):210050 PMID: 34255975
- 7. Feltham R et al.. 2012. IAPS and ubiquitylation.. IUBMB Life 64(5):411-8 PMID: 22362579
- 8. Sharma M et al.. 2015. Myostatin: expanding horizons.. IUBMB Life 67(8):589-600 PMID: 26305594
